EGFR and non-small cell lung carcinoma: miR-21 may induce EGFR-TKI resistance in NSCLC cells by activating the PI3K/AKT pathway through PTEN and PDCD4 inhibition [154], and its circulating expression level has also been correlated with the EGFR-TKI treatment response.